Drug Profile
LY 3025876
Alternative Names: LY3025876Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (SC, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Singapore (SC, Injection)
- 01 Dec 2014 Eli Lilly completes a phase I trial in Type-2 diabetes mellitus in USA (NCT01870297)